ABUS

NASD Arbutus Biopharma Corporation
Oct 14, 2026 · 5:46 AM ET LAST TRADE Market Closed

$4.10 ↓ -0.01 (-0.24%) Trading Down from the previous close of $4.11

YTD change
-14.76%
vs 20-day SMA
-11.98%
vs 200-day SMA
-9.43%

Price ranges

Previous day
$4.05 $4.16
open $4.13 close $4.11
-$0.02 (-0.48%)
Today
$0.00 $0.00
$4.10
Past week
$4.05 $4.48
from $4.48 now $4.10
-$0.38 (-8.48%)
Past month
$4.05 $5.10
from $5.06 now $4.10
-$0.96 (-18.97%)
This year
$3.50 $5.45
from $4.81 now $4.10
-$0.71 (-14.76%)

Price & Performance

-0.24 (-5.52%) / 6M

$4.02$4.45$4.88$5.31Apr 14Jul 15Oct 13

Signals & Sentiment

Momentum, market sentiment, and recent alerts

Not So Good
  • The stock is 67.5% away from all-time highs of $12.60
  • ABUS is down 15% since the beginning of the year
  • ABUS is down 3% over the past 12 months
  • ABUS is down 19% over the past 1 month
  • 22% of all ABUS investors are betting against ABUS

ABUS reads not so good: price sits below both the 20- and 200-day averages, the 12-month move is -3.1%.

Financial Strength

Earnings, valuation, and balance sheet

Earnings

Profitable No
EPS $-0.03
Earnings momentum -29.3% Quarterly EPS growth
Quarterly change -29.3%

Valuation

P/E ratio 5.34
Enterprise value $730.5M
Beta 0.46

Balance sheet & scale

Income$152.7K
Revenue$180.7M
Cash$92.6M
Debt$3.6K
Income / Debt 42.12×

Company & Peers

Company profile and competitor comparison

Company profile

ExchangeNASD
Sector Professional, Scientific, and Technical Services
Industry Group Scientific Research and Development Services
Market cap $811.2M

Arbutus Biopharma Corp. is a clinical-stage biopharmaceutical company, which engages in developing novel therapeutics that target specific viral diseases. It focuses on the development of imdusiran (AB-729), proprietary, conjugated GalNAc, subcutaneously-delivered RNAi therapeutic, and AB-101, proprietary oral PD-L1 inhibitor, for the treatment of chronic hepatitis B (cHBV). The company was founded on October 6, 2005 and is headquartered in Warminster, PA.

Competitor comparison

TickerCompany PriceChange
REGN Regeneron Pharmaceuticals, Inc. $753.12 -1.27%
IQV IQVIA Holdings Inc $260.68 -0.58%
CRL Charles River Laboratories International, Inc. $299.02 -0.94%
ICLR ICON Plc $164.34 -0.04%
IT Gartner, Inc. $196.96 +1.47%

You looked up one stock
Trade Ideas watches them all

Real-time scanning and AI-generated signals across the entire market.

See plans TI Pro Download

Prices and alerts are delayed by at least 20 minutes. Chart history reflects daily closing prices. Information is provided for research purposes only and is not investment advice.